Christoph Lengauer, Curie.Bio | Biotech Founders, Venture Capital | E57

<p>We admire the mountains of Austria with the co-founder of Curie.Bio, a founder-friendly fund that now manages $1.25B and backs 38 portfolio companies.We discuss Curie.Bio’s track record, with its most advanced portfolio candidate Forward Therapeutics in Phase I.We also talk about major bottom-up successes including argenx, Ascendis and Genmab, and how life sciences investing differs from tech investing.Christoph also explains his ‘rebel’ mindset and why founders shouldn’t accept the status quo.</p><p>---This episode is brought to you by Avance, where European biotech turns for trusted financial advice. Learn more at <a href="https://bit.ly/flot-avance" target="_blank" rel="ugc noopener noreferrer">https://bit.ly/flot-avance</a>---</p><p>⭐️ ABOUT THE SPEAKER</p><p>Christoph co-founded of Curie.Bio in 2022, after serving as Partner at Third Rock Ventures for 6 years. He also had leading roles at Blueprint Medicines for ten years, and at MOMA Therapeutics for one year.He has also been an Adjunct Associate Professor at Johns Hopkins University for more than 20 years, with past roles at Celsius Therapeutics, Sanofi, and Novartis. 🔗 LINKS MENTIONED</p><ul><li>Curie.Bio — <a href="https://curie.bio/" target="_blank" rel="ugc noopener noreferrer">https://curie.bio/</a></li><li>Christoph Lengauer — <a href="https://www.linkedin.com/in/christoph-lengauer-75b7961b/" target="_blank" rel="ugc noopener noreferrer">https://www.linkedin.com/in/christoph-lengauer-75b7961b/</a></li><li>Sanofi to acquire Blueprint Medicines — <a href="https://www.sanofi.com/en/media-room/press-releases/2025/2025-06-02-05-00-00-3091541" target="_blank" rel="ugc noopener noreferrer">https://www.sanofi.com/en/media-room/press-releases/2025/2025-06-02-05-00-00-3091541</a></li><li>Forward Therapeutics Announces $50 Million Series A Financing —<a href="https://forward-tx.com/press-release/forward-therapeutics-announces-50-million-series-a-financing/" target="_blank" rel="ugc noopener noreferrer">https://forward-tx.com/press-release/forward-therapeutics-announces-50-million-series-a-financing/</a></li><li>Gilead to Acquire Tubulis — <a href="https://www.gilead.com/news/news-details/2026/gilead-to-acquire-tubulis-adding-potentially-best-in-class-antibody-drug-conjugate-and-next-generation-platform-to-further-strengthen-oncology-pipeline" target="_blank" rel="ugc noopener noreferrer">https://www.gilead.com/news/news-details/2026/gilead-to-acquire-tubulis-adding-potentially-best-in-class-antibody-drug-conjugate-and-next-generation-platform-to-further-strengthen-oncology-pipeline</a></li><li>Dominik Schumacher, Tubulis 🇩🇪 | Founder-led ADC Biotech ⭐️ | E19 — <a href="https://flot.bio/episode/dominik-schumacher-tubulis/" target="_blank" rel="ugc noopener noreferrer">https://flot.bio/episode/dominik-schumacher-tubulis/</a></li><li>Sander Slootweg, Forbion 🇳🇱 | European Biotech Investment, Venture Capital | E56 — <a href="https://flot.bio/episode/sander-slootweg-forbion-eu-biotech-investment/" target="_blank" rel="ugc noopener noreferrer">https://flot.bio/episode/sander-slootweg-forbion-eu-biotech-investment/</a></li></ul><p>📜 TRANSCRIPT</p><p>Read the full transcript here: <a href="https://flot.bio/episode/christoph-lengauer-curiebio-biotech-founders/" target="_blank" rel="ugc noopener noreferrer">https://flot.bio/episode/christoph-lengauer-curiebio-biotech-founders/</a></p><p><br></p><p>📖 BLOGS BASED ON THIS EPISODE:</p><ul><li>The Biotech Equity Gap: Why Curie.Bio is Re-Writing the Founder Playbook: <a href="https://flot.bio/biotech-equity-founder/" target="_blank" rel="noreferrer noopener">https://flot.bio/biotech-equity-founder/</a></li><p><br></p></ul><p>💸 DONATE</p><p>We welcome donations from individuals and businesses to support our podcast and allow us to create even more content: <a href="https://www.paypal.me/PhilipHemme" target="_blank" rel="ugc noopener noreferrer">https://www.paypal.me/PhilipHemme</a></p><p>⭐️ SPONSORSHIP</p><p>Ready to amplify your